This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 8 of 14 for:    Provectus

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
Sponsor:
Information provided by (Responsible Party):
Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
ClinicalTrials.gov Identifier:
NCT02557321
First received: September 20, 2015
Last updated: April 27, 2017
Last verified: April 2017
  Purpose
This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition. Stage IV metastatic melanoma patients with at least one injectable cutaneous or subcutaneous lesion who are candidates for pembrolizumab will be eligible for study participation. In the Phase 1b portion of the study, all participants will receive the combination of IL PV-10 and pembrolizumab (i.e., PV-10 + standard of care). In the subsequent Phase 2 portion of the study participants will be randomized 1:1 to receive either the combination of IL PV-10 and pembrolizumab or pembrolizumab alone (i.e., PV-10 + standard of care vs. standard of care).

Condition Intervention Phase
Melanoma Drug: PV-10 Drug: Pembrolizumab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. ):

Primary Outcome Measures:
  • Safety and tolerability of the combination regimen assessed by adverse events (AEs) [ Time Frame: Start of treatment until 4 weeks after final administration of PV-10 ]
    Phase 1b: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs

  • Progression Free Survival (PFS) [ Time Frame: Up to 24 months from initiation of study treatment ]
    Phase 2: Response evaluated by blinded independent review committee assessment per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1


Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Up to 24 months from initiation of study treatment ]
    Phase 1b: Response evaluated per RECIST 1.1

  • Objective Response Rate (ORR) [ Time Frame: Up to 24 months from initiation of study treatment ]
    Phase 1b and 2: Response evaluated per RECIST 1.1

  • Change in immune biomarkers [ Time Frame: Up to 28 weeks from initiation of study treatment ]
    Phase 1b: Peripheral Blood Mononuclear Cells (PBMCs) assessed vs. baseline values for changes in T cell populations

  • Overall Survival (OS) [ Time Frame: 24 months from initiation of study treatment for last subject randomized ]
    Phase 1b and 2

  • Safety and tolerability of the combination regimen assessed by adverse events (AEs) [ Time Frame: Start of treatment until 4 weeks after final administration of PV-10 ]
    Phase 2: Safety and tolerability of the combination regimen will be assessed by monitoring the frequency, duration, severity and attribution of adverse events (AEs) and toxicities requiring discontinuation of study treatment, and evaluating changes in laboratory values and vital signs


Estimated Enrollment: 144
Study Start Date: October 2015
Estimated Study Completion Date: November 2023
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase 1b
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Drug: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
Other Name: Rose Bengal Disodium
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
Experimental: Phase 2 (Arm 1)
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Drug: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
Other Name: Rose Bengal Disodium
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
Active Comparator: Phase 2 (Arm 2)
Pembrolizumab (2 mg/kg every 3 weeks)
Drug: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)

Detailed Description:

Up to 24 eligible subjects will be enrolled in the Phase 1b portion of the study. Each subject in this cohort will receive the combination of IL PV-10 and pembrolizumab.

A total of an estimated 120 eligible subjects will be randomized in a 1:1 ratio to the two treatment arms (i.e., PV-10 + pembrolizumab or pembrolizumab alone) in the Phase 2 portion of the study. This number of subjects may be modified based on emerging evidence of preliminary efficacy and effect size from the Phase 1b portion of the study.

Subjects assigned to receive PV-10 in Phase 1b and 2 will receive initial IL PV-10 to their injectable cutaneous and subcutaneous lesions commencing on study Day 1 for up to 13 weeks (i.e., investigational Treatment Phase of the study). PV-10 may be re-administered at 21-day (3-week) intervals during the Treatment Phase of the study to any remaining, uninjected cutaneous and subcutaneous lesions until all injectable cutaneous and subcutaneous lesions have been injected. Lesions that fail to exhibit complete ablation may be re-injected on this schedule.

Pembrolizumab will be administered at 21-day (3-week) intervals per prescribing information (label) commencing on study Day 1 for up to 24 months or until disease progression, toxicity requiring discontinuation of study treatment or study termination.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 years or older, male or female.
  2. Histologically or cytologically confirmed diagnosis of melanoma.
  3. Stage IV melanoma for which surgery is not recommended.
  4. At least 1 cutaneous or subcutaneous Injectable Lesion with longest diameter at least 5 mm.
  5. A minimum of 1 measurable Target Lesion (i.e., ≥ 10 mm longest diameter).
  6. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.
  7. Clinical Laboratories:

    • absolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelet count ≥100 x 109/L
    • estimated creatinine clearance (CrCl, by Cockcroft-Gault formula) or estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
    • total bilirubin ≤ 3 times the upper limit of normal (ULN)
    • aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal (ULN)
  8. Thyroid function abnormality ≤ Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2.

Exclusion Criteria:

  1. Untreated or clinically active melanoma brain metastases.

    • Subjects with ≤ 3 brain metastases and each ≤ 1 cm size that were treated with either surgical resection and/or radiation therapy are eligible for study participation provided (a) there is no evidence of progressive central nervous system (CNS) disease on brain imaging at least 30 days after definitive treatment and (b) the subject is not taking prednisone at >10 mg or equivalent daily.
    • Subjects with > 1 cm or > 3 in number treated brain metastases are eligible for study participation provided (a) there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy and (b) if the subject is not taking prednisone at >10 mg or equivalent daily.
  2. Prior treatment with PV-10 or any anti-PD-1 antibody

    • Subjects previously treated with any anti-PD-L1 antibody are eligible for study participation).
  3. Prior cancer therapy or anti-cancer vaccine within 4 weeks of initial study treatment.
  4. Known sensitivity to any of the products or components to be administered during dosing.
  5. Concurrent or Intercurrent Illness:

    • History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other systemic autoimmune disease.
    • Evidence of clinically significant immunosuppression.
    • Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity.
    • Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity.
    • Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
    • Uncontrolled thyroid disease or cystic fibrosis.
    • Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders.
    • Malignancy other than melanoma within 2 years of enrollment except for: adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer.
  6. Pregnancy:

    • Female subjects who are pregnant or lactating.
    • Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment.
    • Female subjects of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) who are not using highly effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures).
    • Male subjects who are unwilling to use acceptable method of effective contraception.
  7. Subjects unable to comprehend and give informed consent are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02557321

Contacts
Contact: Eric Wachter, Ph.D. 865-769-4011 ext 23 wachter@pvct.com

Locations
United States, California
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Jaime Richardson, RN, BSN, OCN    310-423-2133    Jaime.Richardson@cshs.org   
Principal Investigator: Richard Essner, MD         
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Jodie Nunez, MS    813-745-4070    Jodie.Nunez@moffitt.org   
Principal Investigator: Jonathan Zager, MD         
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Darcie Findley, CCRC    603-650-4595    darcie.l.findley@hitchcock.org   
Principal Investigator: Keisuke Shirai, MD         
United States, Pennsylvania
St Luke's University Hospital and Health Network Recruiting
Easton, Pennsylvania, United States, 18045
Contact: Robyn Rex    484-503-4152    Robyn.Rex@sluhn.org   
Principal Investigator: Sanjiv Agarwala, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77230
Contact: Donna Branham    713-563-3527    dbranham@mdanderson.org   
Principal Investigator: Merrick I Ross, MD         
Australia, Queensland
Princess Alexandra Hospital Recruiting
Brisbane, Queensland, Australia, 4102
Contact: Janine Thomas       Janine.thomas@mater.uq.edu.au   
Principal Investigator: Mark Smithers, MB BS, FRACS         
Principal Investigator: Victoria Atkinson, MB BS, FRACP         
Sponsors and Collaborators
Provectus Biopharmaceuticals, Inc.
Investigators
Study Director: Eric Wachter, Ph.D. Provectus Pharmaceuticals, Inc.
  More Information

Responsible Party: Provectus Biopharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02557321     History of Changes
Other Study ID Numbers: PV-10-MM-1201
Study First Received: September 20, 2015
Last Updated: April 27, 2017

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Antineoplastic Agents

ClinicalTrials.gov processed this record on July 21, 2017